



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-547/S-066

NDA 50-596/S-035

Sanofi-aventis, US, L.L.C.
Attention: Bradley Jones, RAC
Specialist, Heritage Product Support
55 Corporate Drive
Bridgewater, NJ 08807

Dear Mr. Jones:

Please refer to your supplemental new drug applications dated May 25, 2007, received May 29, 2007 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Claforan® (cefotaxime sodium) sterile IM/IV and Claforan® (cefotaxime sodium) injection.

These applications are subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

These “Changes Being Effected” supplemental new drug applications provide for revisions to the WARNINGS section and the PRECAUTIONS/Information for Patients subsection of the package inserts to add additional information regarding *Clostridium difficile* associated disease (CDAD).

We completed our review of these applications, and they are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text. The final printed labeling (FPL) must be identical to the enclosed labeling dated May 25, 2007.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. For administrative purposes, designate these submissions "**FPL for approved supplements NDA 50-547/S-066, 50-596/S-035.**" Approval of these submission(s) by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Katherine A. Laessig, MD

Deputy Division Director

Division of Anti-Infective and Ophthalmology Products

Office of Antimicrobial Products

Center for Drug Evaluation and Research

Enclosure: Labeling submitted on May 25, 2007

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Kathrine Laessig
2/21/2008 11:21:14 AM